The Food and Drug Administration (FDA) has approved a labeling update for Vemlidy (tenofovir alafenamide; Gilead Sciences) to include dosage information regarding its use in adults with end-stage renal disease (ESRD; CrCl <15mL/min) who are receiving chronic hemodialysis.
Drugs in the Pipeline
Intradialytic hypotension is a common complication of hemodialysis and can lead to increased morbidity and mortality among patients with end-stage renal disease.
AHA 2017 Scientific Sessions
End-stage renal disease patients on dialysis with atrial fibrillation are at high risk for thrombotic complications.
For patients with chronic kidney disease (CKD), a diet that stresses healthy food vs. individual ingredients may help reduce the risk of early death, a study published in the Clinical Journal of the American Society of Nephrology has found.
A higher allopurinol dose provided a protective effect against incident renal failure in elderly patients, according to a study published in Annals of the Rheumatic Diseases.
Uric acid-lowering therapy might improve kidney outcomes, including kidney failure events, proteinuria, and the rate of change in eGFR, and seem to reduce the risk of cardiovascular events in adults with CKD.
Temixys combines lamivudine (3TC) and tenofovir disoproxil fumarate (TDF), which are 2 nucleoside reverse transcriptase inhibitors.
The Food and Drug Administration (FDA) has approved Zulresso (brexanolone; Sage Therapeutics) injection for the treatment of postpartum depression in adult women, the first drug to be approved for this indication. Zulresso, an analogue of the endogenous human hormone allopregnanolone, is intended for continuous intravenous (IV) infusion over 2.5 days following a titration schedule. It…
Based on the pathophysiological and clinical characteristics of N-ERD, anti-IL 5 therapy may be effective in this patient subgroup.
ACR/ARHP 2016 Annual Meeting
The trial compares short- and long-term outcomes of Cimzia and Humira in RA